Mirion makes radiation detection and measurement gear for hospitals, nuclear plants, and defense—think Geiger counters for professionals, plus imaging and safety tools for cancer treatment.
Revenue hit USD 0.93B in 2025 with a 47.4% gross margin, but net margin was just 3.1%—money comes from recurring service and consumables, though thin after costs.
Regulatory approvals and safety certifications create high switching costs for hospitals and nuclear operators, but competitors like Thermo Fisher Scientific and Canberra Industries offer similar tech, and budget pressure weakens loyalty.
Key events, in time order
Partnership targets DOE and federal nuclear cleanup, expanding Mirion's market in nuclear waste management
Revenue $266.8M missed est., adj. EPS $0.12 beat, FY26 guide affirmed
None yet
None yet
Leon Cooperman's Q2 portfolio update shows a significant stake in Mirion Technologies ($MIR), indicating a potential fundamental thesis or position statement.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
